Risk factors for lymph node metastasis in patients with pancreatic neuroendocrine neoplasms

doi:10.5306/wjco.v13.i6.520

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3245)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

188

WORD

HTML

1239

Figures (1-2)

246

Tables (1-2)

236

Sum=1952

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

321

Download

972

Sum=1293

Jun 24, 2022 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Jun 24, 2022; 13(6): 520-528
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.520

Full Size Figure Download Figure

Figure 2 Overall survival after surgery of 82 patients according to the presence of lymph node metastasis. The cumulative overall survival rate after surgery among patients who had no lymph node (LN) metastasis was significantly higher than that for those who had LN metastasis. LN: Lymph node.

Citation: Nakao Y, Hayashi H, Yamashita YI, Takashi O, Matsumura K, Uemura N, Kitamura F, Itoyama R, Yusa T, Taki K, Miyata T, Higashi T, Nakagawa S, Okabe H, Imai K, Baba H. Risk factors for lymph node metastasis in patients with pancreatic neuroendocrine neoplasms. World J Clin Oncol 2022; 13(6): 520-528
URL: https://www.wjgnet.com/2218-4333/full/v13/i6/520.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i6.520